1-哌啶乙酸,3-[[(1,1-二甲基乙氧基)羰基]氨基]-a-3-噻嗯基- | 51900-85-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-哌啶乙酸,3-[[(1,1-二甲基乙氧基)羰基]氨基]-a-3-噻嗯基-
• 中文别名: 对乙酰氨基酚-阿司匹林混合物
• 英文名称: Safapryn
• 英文别名: 2-acetyloxybenzoic acid;N-(4-hydroxyphenyl)acetamide
• CAS: 51900-85-7
• 化学式: C17H17NO6
• 分子量: 331.32
• InChiKey: ZDPCIXZONVNODH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对乙酰氨基酚 、 阿司匹林 、 、 Stearic acid magnesium salt 在 阿司匹林 作用下， 反应 0.02h， 生成 1-哌啶乙酸,3-[[(1,1-二甲基乙氧基)羰基]氨基]-a-3-噻嗯基-
  参考文献：
  名称：

  Powdered/microfibrillated cellulose

  摘要：

  本文描述了一种新的纤维素辅料，适用于在固体剂型的开发中作为粘合剂、填充剂和/或崩解剂，以及在制备局部制剂时作为增稠剂或药物载体。该纤维素辅料是通过在水性碱金属氢氧化物溶液中浸泡纤维素源而形成的。然后再再生纤维素，清洗，并可选地用稀矿物酸水解。该纤维素辅料在局部制剂的水性分散和纤维素珠的制造中也很有用。

  公开号：

  US20020061335A1

文献信息

• Ingestible aggregate and delivery system incorporating the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0190826A2

  公开（公告）日：1986-08-13

  The present invention relates to an ingestible aggregate comprising a pre-swelled substantially anhydrous hydrocolloid and a substrate. More particularly this invention relates to an aggregate having as a substrate a dietary fiber and/or drug wherein the composition can be administered in a therapeutically effective amount Hydrocolloids useful include natural and modified gums, celluloses, modified celluloses, pectins, mucillages, modified starches, noncellulose polysaccharides, algal polysaccharides and mixtures thereof. The aggregate should be in the size range of about 4 to about 70 U.S. mesh. The unpleasant taste and mouthfeel of the fiber and/or drug is effectively masked and substantial hydration is delayed until the compositions reaches the stomach. The compositions are substantially more palatable, devoid of graininess, bitterness or fibrous texture. The pleasant taste of the composition encourages patient compliance with their fiber or drug therapy.

  本发明涉及一种可食用的聚合体，它包括一种预膨胀的基本无水的水胶体和一种基质。更具体地说，本发明涉及一种以膳食纤维和/或药物为基质的聚合体，其中的组合物可以治疗有效量给药。有用的水胶体包括天然胶和改性胶、纤维素、改性纤维素、果胶、粘液质、改性淀粉、非纤维多糖、海藻多糖及其混合物。聚合体的大小范围应在约 4 到约 70 美国目之间。纤维和/或药物的难闻味道和口感会被有效掩盖，大量水合作用会延迟到组合物进入胃部。组合物的口感更好，没有颗粒感、苦味或纤维质感。组合物令人愉悦的口感可促使患者坚持纤维或药物治疗。
• A novel drug delivery system and method of preparation thereof
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0177368A2

  公开（公告）日：1986-04-09

  There is disclosed a drug delivery system comprising; (a) a drug; and (b) a hydrophobic matrix comprising : (i) an emulsifier; (ii) an edible material having a melting point in the range of from 25°C to 100°C chosen from fatty acids having an iodine value of from 1 to 10, natural waxes, synthetic waxes and mixtures thereof; and (iii) at least one glyceride.

  本发明公开了一种药物输送系统，该系统包括 (a) 药物 (b) 一种疏水基质，包括： (i) 一种乳化剂 (ii) 熔点在 25°C 至 100°C 范围内的可食用材料，可从碘值为 1 至 10 的脂肪酸、天然蜡、合成蜡及其混合物中选择；以及 (iii) 至少一种甘油酯。
• Foam compositions, foam matrices and methods
  申请人：COVALON TECHNOLOGIES INC.

  公开号：US11517644B2

  公开（公告）日：2022-12-06

  Disclosed herein are matrices, compositions and methods of making matrices. The matrix comprises a biomolecule and the matrix is a dried, cross-linked foam. The matrix is not lyophilized. The method comprises foaming the composition, crosslinking the composition and drying the composition. Matrices disclosed herein are useful as wound dressings and treating wounds.

  本文公开了基质、组合物和制作基质的方法。基质包括生物大分子，基质是干燥的交联泡沫。基质不是冻干的。该方法包括发泡组合物、交联组合物和干燥组合物。本文公开的基质可用作伤口敷料和治疗伤口。
• Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
  申请人：——

  公开号：US20020146457A1

  公开（公告）日：2002-10-10

  A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymer, an active agent, and a solvent. A second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The discontinuous first phase is separated from the continuous second phase. The residual level of solvent in the discontinuous first phase is reduced to less than about 2% by weight.

  一种制备可生物降解的生物相容性微粒的方法。制备第一阶段，其中包括可生物降解的生物相容性聚合物、活性剂和溶剂。制备第二相。第一相和第二相结合形成乳液，其中第一相是不连续的，第二相是连续的。将不连续的第一相从连续的第二相中分离出来。非连续第一相中溶剂的残留量按重量计降至约 2% 以下。
• Pharmaceutical composition comprising a 5-aroyl-1-C1-5 alkyl-pyrrole-2-acetic acid compound and acetaminophen or acetylsalicylic acid
  申请人：McNeilab, Inc.

  公开号：EP0006845B1

  公开（公告）日：1982-02-03